The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Sandoz Japan Gets OK to Add New Manufacturing Site for Anapeine
Sandoz has obtained the thumbs-up of Japanese regulatory authorities for the addition of a new manufacturing site for some dosage versions of its long-acting local anesthetic Anapeine (ropivacaine), which has been running short due to restricted shipments. Anapeine is available…
To read the full story
Related Article
- Terumo Puts Brake on Supply of Anapeine Generics
November 21, 2024
- Terumo Rolls Out Anapeine Generics after Expedited Listing
November 13, 2024
- Anapeine Generics Get Expedited Listing amid Supply Crunch
November 12, 2024
- Sandoz Gives Update on Anapeine Supply after Manufacturing Change
October 30, 2024
- Local Anesthetic Supply Won’t Recover Soon Despite New Site Approval: Specialist
October 28, 2024
- Supply of Anapeine Generic to Start by Year-End: Minister
October 9, 2024
- Anapeine Restriction Forcing Sandoz to Curb Supply of More Local Anesthetics
August 7, 2024
- Local Anesthetic Runs Short in Japan Due to Curbed Supply of Sandoz’ Anapeine
July 31, 2024
BUSINESS
- Sanofi Files Dupixent for CSU in Children Aged 2-11 in Japan
December 26, 2025
- Enhertu Wins 5th China Indication in HER2-Low/Ultralow Breast Cancer
December 26, 2025
- SymBio Bags Rights to Develop Antiviral Brincidofovir for Alzheimer’s
December 26, 2025
- Dayvigo Wins Triple Crown in November HP Promotion List: Intage
December 26, 2025
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…